Charles Schwab (SCHW)
(Real Time Quote from BATS)
$62.30 USD
-5.13 (-7.61%)
Updated Jul 17, 2024 12:24 PM ET
4-Sell of 5 4
C Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
SCHW 62.30 -5.13(-7.61%)
Will SCHW be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SCHW based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SCHW
Charles Schwab (SCHW) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Schwab's (SCHW) Q2 Earnings & Revenues Meet, Shares Slide
SCHW: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Charles Schwab Corporation (SCHW) Meets Q2 Earnings Estimates
Low Market Volatility to Hurt Schwab's (SCHW) Q2 Earnings
The Charles Schwab Corporation (SCHW) to Report Q2 Results: Wall Street Expects Earnings Growth
Other News for SCHW
KBW Reaffirms Their Buy Rating on Charles Schwab (SCHW)
Deutsche Numis Keeps Their Buy Rating on Charles Schwab (SCHW)
Argus Research Gives a Buy Rating to Charles Schwab (SCHW)
Notable Two Hundred Day Moving Average Cross - SCHW
Hold Rating on Charles Schwab Amid Earnings Concerns and Valuation Adjustment